Research programme: infectious disease vaccines - Tetragenetics

Drug Profile

Research programme: infectious disease vaccines - Tetragenetics

Alternative Names: H5N1 influenza A vaccine - Tetragenetics; Influenza A virus vaccine H5N1 - Tetragenetics; Malaria vaccine - Tetragenetics

Latest Information Update: 03 Apr 2013

Price : $50

At a glance

  • Originator Tetragenetics
  • Class Subunit vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Influenza A virus infections; Malaria

Most Recent Events

  • 03 Apr 2013 Preclinical development is ongoing the USA
  • 01 Nov 2012 Tetragenetics receives phase II Grand Challenges Explorations grant from Gates Foundation for development Malaria vaccine
  • 01 Jan 2012 Preclinical trials in Influenza A virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top